IDEAYA Biosciences’ Post

View organization page for IDEAYA Biosciences, graphic

12,695 followers

1mo

IDEAYA Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development: https://lnkd.in/gsbecTBD

IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development

media.ideayabio.com

18 Comments

Sara Baldwin

Executive Assistant | C-Suite Support | Notary Public

1mo

Congrats Daniel Simon they're lucky to have you on board and now you're in my area, enjoy the fog 🤣

Sara Lapomarda

Commercial leader expert in early stage Oncology Diagnostics commercialization

1mo

Congrats Daniel Simon!!! I know you’ll help this organization to the next level!! Keep up the great work!!

Josh Wein

Marketing and Communications

1mo

Huge get for IDEAYA

Md Abul Fazal

22K Pharmaceutical Professionals connection Across the World.Pharma finished Products Exporter.Oncology, Hematology, Antiviral.

1mo

Exciting times! Congratulations 🎈

Mark Landers

VP, Precision Medicine at Akoya Biosciences - The Spatial Biology Company | Bringing Spatial To The Clinic

1mo

Congrats Daniel!!! They are lucky to have you!

Don Lim

Sr. Recruits-a-Lot

1mo

Great move, Daniel Simon! Congrats to Yujiro and the IDEAYA team!

Shivam K. Shodhan

Life Sciences Executive | Strategy, CorpDev, HR/People, BizOps Leadership

1mo

Congrats, Daniel!

Kelly Gordon, Ph.D., MB (ASCP)

1mo

Congrats Daniel Simon!

Debanjan Ray

1mo

Congratulations!

Matthew Pink

Vice President, Business Development | Strategic Partnerships | Alliance Management

1mo

Congratulations!

See more comments

To view or add a comment, sign in

More Relevant Posts

IDEAYA Biosciences

12,695 followers
11h
Report this post
IDEAYA Announces Pricing of Public Offering: https://lnkd.in/gvHKGftk

IDEAYA Announces Pricing of Public Offering

media.ideayabio.com
Like Comment
To view or add a comment, sign in
IDEAYA Biosciences

12,695 followers
1d
Report this post
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants: https://lnkd.in/g95cKRSf

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

media.ideayabio.com
Like Comment
To view or add a comment, sign in
IDEAYA Biosciences

12,695 followers
2d
Report this post
IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer: https://lnkd.in/gnjZ4A94
3 Comments
Like Comment
To view or add a comment, sign in
IDEAYA Biosciences

12,695 followers
4d
Report this post
IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024: https://lnkd.in/gFxJayuU

IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024

media.ideayabio.com
Like Comment
To view or add a comment, sign in
IDEAYA Biosciences

12,695 followers
1w
Report this post
IDEAYA Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4): https://lnkd.in/grQHKRbP
Like Comment
To view or add a comment, sign in
IDEAYA Biosciences

12,695 followers
2w
Report this post
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer: https://lnkd.in/gWX_6n3z
Like Comment
To view or add a comment, sign in
IDEAYA Biosciences

12,695 followers
2w
Report this post
IDEAYA Announces Clinical Program Updates for IDE397, a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors: https://lnkd.in/gAKGVgiG
1 Comment
Like Comment
To view or add a comment, sign in
IDEAYA Biosciences

12,695 followers
1mo
Report this post
We are thrilled to announce our 5-year anniversary of being listed on NASDAQ. Thank you to our employees, patients we serve, collaboration partners and shareholders for being part of our journey to deliver innovative precision medicine therapies for cancer patients!
9 Comments
Like Comment
To view or add a comment, sign in
IDEAYA Biosciences

12,695 followers
1mo
Report this post
IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study: https://lnkd.in/dDVUhDZu
Like Comment
To view or add a comment, sign in
IDEAYA Biosciences

12,695 followers
1mo
Report this post
Yujiro Hata, President and CEO of IDEAYA Biosciences, discusses the potential of precision medicine oncology in the Pathfinders Podcast hosted by Joseph Coletti of RBC Capital Markets: https://lnkd.in/gfb7Wr7j
Like Comment
To view or add a comment, sign in

12,695 followers

View Profile Follow

IDEAYA Biosciences’ Post

More Relevant Posts

Explore topics